The recent attainment of the CE mark for Medtronic‘s Percept deep brain stimulation (DBS)  system marks a significant milestone in the field of neurostimulation, driving advancements in tailored therapies. The system’s personalized approach mirrors a broader industry shift, shaping neurostimulation technologies. With a focus beyond traditional neurological disorders, the CE mark propels the market towards a promising future in personalized healthcare solutions, according to GlobalData, a leading data and analytics company.

GlobalData anticipates the market share of DBS systems to grow as the neuromodulation market expands. The global neuromodulation market is expected to grow at a compound annual growth rate (CAGR) of 6.3% from $6.6 billion in 2022 to reach $10.7 billion in 2030.

Cynthia Stinchcombe, Medical Devices Analyst at GlobalData, says: “The market is shifting towards targeting other indications, including depression. Abbott‘s DBS system has received FDA breakthrough designation for the treatment of treatment-resistant depression, expanding the indication of neuromodulation devices. Functional Neuromodulation’s Vercise DBS system has also received breakthrough device designation for treating patients with mild probable Alzheimer’s disease.”

Neurostimulation technologies are being targeted for various indications in the medical field. Some of these indications include chronic pain, neurological disorders, depression, migraines, and urinary incontinence.

Stinchcombe comments: “The projected expansion of the neuromodulation market, with DBS systems leading, indicates a promising shift. Abbott’s FDA breakthrough for depression and Vercise’s Alzheimer’s device designation signify a growing recognition of neurostimulation’s broader medical applications beyond traditional neurological disorders.”

The recent advancements in neurostimulation, exemplified by Medtronic’s Percept DBS System and supported by GlobalData’s insights, signal a transformative shift towards tailored therapies.

Stinchcombe concludes: “With the expanding neuromodulation market and breakthrough designations for diverse indications, neurostimulation technologies are set to reshape medical treatments, extending beyond traditional neurological disorders into personalized healthcare solutions.”